Maintain NEUTRAL and DCF-derived MYR1.34 TP, 8% upside. Duopharma Biotech reported 3Q24 core earnings of MYR17.8m, bringing 9M24 to account for 79% and 77% of our and Street estimates. Results were deemed in line as 4Q24 is typically a softer period. Despite the public sales segment was encouraging, we are of the view that some sticky costs structure (higher staff cost and electricity tariff) together with subdued consumer demand for supplement products are set to weigh on its profitability.
Result overview. 3Q24 core earnings grew 47% YoY, primarily driven by the increase sales from the public sector (given the renewal of the approved products list (APPL) contract in May), offset against by the subdued performance from the consumer healthcare (CHC) segment. Depreciation charges and finance cost rose 15% and 23% YoY, of which its K3 production facility received the certificate of completion and compliance (CCC) in 2Q23 (with both costs are no longer allow to be capitalised).
Margin overview. 3Q24 GPM contracted 1.3ppts YoY in view of the effect of the strengthening of the USD against MYR in the earlier part of 2024 given its key raw material – active pharmaceutical ingredient price (API) is denominated in USD. Core margin was largely flattish QoQ and YoY at 8.5% (3Q24: 8%; 3Q23: 7.2%) due to the higher depreciation charges and increased operational cost associated with K3 facility’s full operation.
Outlook. The USD had depreciated by 6% QoQ vs the MYR in 3Q24. We expect this to bodes well for DBB given 50% of its cost of sales (ie API) are denominated in the USD. Elsewhere, we believe the impact will only be felt by 4Q24 given the time lag effect required to consume the raw material it had previously replenished. Its prospects should also be underpinned by: i) The recent additional letter of award by the Ministry of Health (MOH) for the supply of pharmaceutical products under the APPL contract (bringing its product range to 96 from 86); and ii) potential renewal of human insulin supply contract with MOH (expected to conclude by 1Q25).
Earnings estimates. We make no changes to our estimates pending further details in the upcoming result briefings. While we are optimistic on the pickup in the public sales segment, ongoing cost pressures and persists sluggish CHC sales are expected to weigh on DBB’s profitability moving forward. The stock is currently trading at 14.5x 2025F P/E, or -0.6SD from its 5-year historical mean of 17x. Our TP incorporates a 4% ESG premium given DBB’s ESG score is above the country median. Downside risks to our call include lower-than-expected sales volumes and stronger USD/MYR. The converse represents the upside risks.
Be the first to like this. Showing 0 of 0 comments
Post a Comment
People who like this
Featured Posts
MQ Trader
Introducing MY's First IPO Fund for Sophisticated Investors!
MQ Chat
New Update. Discover investment communities that resonate with your ideas
MQ Trader
M & A Value Partners IPO Equity Fund has been launched - Targeted 13% Return p.a
Latest Videos
0:17
New IPO: A homegrown air fragrance company, Vanzo Holdings Berhad aims to list on the Ace Market!
MQ Trader 172 views | 1 d ago
0:17
New IPO: Winstar Capital Berhad, a specialist in the extrusion of aluminium profiles and fabrication of aluminium ladders aims to list on the ACE Market!
MQ Trader 331 views | 2 d ago
0:17
New IPO: Topvision Eye Specialist Berhad, specializing in medical eye care services aims to list on the ACE Market!
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....